News & Views | Telix Pharmaceuticals Limited

First Australian Patient Dosed in ZIRCON Phase III Trial

Telix Pharmaceuticals Limited is pleased to announce that the first Australian patient has been added to the Phase III ZIRCON study. The first Australian patient was dosed with TLX250-CDx at Olivia Newton-John Cancer and Wellness Centre (Austin Health) on 20th August 2019, as part of the international ZIRCON (Zirconium Imaging in Renal Cancer Oncology) study.

Telix Pharmaceuticals Announces Results of Successful SPP

Telix Pharmaceuticals Limited is pleased to advise that, at closing on Friday 16th August 2019, subscriptions under the Company’s Share Purchase Plan (“SPP”) totaled approximately $9.6 million.

Telix Pharmaceuticals to Present at Jefferies Healthcare Conference

Telix Pharmaceuticals is pleased to announce Telix’s CEO, Dr. Christian Behrenbruch will present at the Jefferies Healthcare Conference at the Grand Hyatt Hotel in New York at 8:00 AM EDT on Tuesday 4th June 2019.

Telix Pharmaceuticals Annual Report 2018

Telix Pharmaceuticals Limited is pleased to provide its Annual Report 2018.

Telix Pharmaceuticals launches information site on illumet™ prostate cancer imaging product

Telix has just launched an information site on our illumet™ prostate cancer imaging product. The website provides an informative depository about how the product works and its potential in clinical use for prostate cancer.

Strategy Update – Acceleration of Prostate Cancer Therapy Program

Telix Pharmaceuticals Limited today announced a strategy update for the TLX591 (prostate therapy) program.

Telix Pharmaceuticals Ltd Detailed Program Update January 2019

Telix Pharmaceuticals Limited is pleased to provide a detailed Program Update January 2019.

Telix Pharmaceuticals & Radboud University Medical Centre Conclude Clinical Collaboration Agreement

Telix Pharmaceuticals has today announced a clinical collaboration with Radboud University Medical Center.

BioSpectrum Asia Interview with Dr Nishimura on APAC Oncology Market

Telix is pleased to provide details of BioSpectrum Asia interview with Telix Japan President & COO Dr Shintaro Nishimura on the APAC oncology market & opportunities/challenges in the Japanese market for radiopharmaceutical products.

Odile Jaume to Lead Telix’s European Operations

Telix Pharmaceuticals Limited is delighted to announce the appointment of Ms. Odile Jaume as President and Chief Operating Officer (COO) of Telix’s European operations.